Haleon PLC's Sponsored (ADR) stock has caught the attention of both investors and analysts alike. The company’s stock price saw a modest increase and its executives have accrued shares through the company’s reward plan. The
UK-based biotech firm has also experienced a ratings upgrade from Barclays due to improving US outlook. However,
short interest in Haleon increases by 31.6%, indicating some investors are expecting the price to fall.
Barclays downgrade Haleon on growth concerns. The professionals see potential in the stock, despite recent weakness, with a
29% potential upside being identified. The Haleon share price had mixed performance ahead of results, dragging down at times but also jumping 2% ahead of February 25 results. Analysts such as
Jim Cramer commented on the struggle of Haleon’s stock, with others like Deutsche Bank setting new price target. Partnerships with other organizations like Salesforce Life Sciences Cloud and Altibbi have been announced, signifying steps towards potential growth. However, the stock faces scandals related to insider trading, the trimming of organic revenue growth, and high short interest, leading to uncertainty and potential risk.
Haleon Stocks News Analytics from Fri, 14 Mar 2025 07:00:00 GMT to Sat, 14 Feb 2026 06:06:02 GMT -
Rating 2
- Innovation 2
- Information 5
- Rumor -2
